The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is:
Does polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will be asked to complete online survey questions regarding their disease prognosis over a 2-year period.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients aged 65 years or older with at least one chronic disease
Exclusion Criteria:
* Patients without chronic diseases
* Patients refused to participate in the study
* Patients with unstable vital signs
Primary outcome measure(s)
Assessing the current status of polypharmacy in elderly patients with chronic diseases in Shaanxi Province via cluster sampling questionnaire survey — Start from enrollment to the end of the study at 2 years. A cluster sampling method was used to conduct a survey on elderly patients with chronic diseases in Shaanxi Province. A questionnaire survey was conducted in different regional locations to collect detailed medication information from patients, such as the number of chronic diseases (types), the types of medications used (types), specific drug names, medication costs (yuan), and duration of medication use (months). Medication habits, such as whether the medication is prescribed by a hospital, purchased from a pharmacy, recommended by friends, or promoted through advertisements, etc. Specific items include concerns about drugs and current physical discomforts. A 5-point Likert scale was adopted, where 1 point indicates "strongly disagree" and 5 points indicate "strongly agree". After questionnaire collection, combined with Beers, STOPP/START, and Chinese elderly PIM criteria, a polypharmacy evaluation and management strategy for these patients was developed.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.